Research has demonstrated superior weight reduction outcomes compared to dual-agonist peptides, with subjects showing significant reductions in body fat, improved insulin sensitivity, and favourable changes in lipid profiles
11 Place in Therapy In the ADA's 2018 Standards of Medical Care in Diabetes , DPP-4 inhibitors are indicated as an add-on option for patients without clinical atherosclerotic CV disease (ASCVD) who are unable to reach goal A1C after taking metformin for 3 months
It must first complete regulatory review and receive approval before it can be prescribed or supplied
Others use it to lose weight while changing nothing else
Exercise also plays a big role in maintaining weight loss
What's particularly fascinating is the timing patients experience noticeable improvements in their most troublesome symptoms within 2-4 weeks of starting low-dose GLP-1 therapy, much faster than traditional MCAS treatments that can take months to show benefit